小児の発熱性好中球減少症におけるLinezolidの有効性と安全性に関する検討

「緒言」Linezolid(LZD)は, オキサゾリジノン系の抗菌薬で, 我が国の添付文書に記載されている適応菌種は, methicillin-resistant Staphylococcus aureus(MRSA)およびvancomycin-resistant Enterococcus faecium(VRE)であるが, methicillin-resistant Staphylococcus epidermidis(MRSE)を含むmethicillin-resistant coagulase negative stapylococcus(MRCNS), penicillin-resis...

Full description

Saved in:
Bibliographic Details
Published in医療薬学 Vol. 41; no. 12; pp. 894 - 899
Main Authors 中村, 安孝, 櫻井, 紀宏, 山田, 康一, 時政, 定雄, 西川, 武司, 新宅, 治夫, 永山, 勝也, 掛屋, 弘
Format Journal Article
LanguageJapanese
Published 一般社団法人日本医療薬学会 10.12.2015
日本医療薬学会
Online AccessGet full text

Cover

Abstract 「緒言」Linezolid(LZD)は, オキサゾリジノン系の抗菌薬で, 我が国の添付文書に記載されている適応菌種は, methicillin-resistant Staphylococcus aureus(MRSA)およびvancomycin-resistant Enterococcus faecium(VRE)であるが, methicillin-resistant Staphylococcus epidermidis(MRSE)を含むmethicillin-resistant coagulase negative stapylococcus(MRCNS), penicillin-resistant Streptococcus pneumoniaeなどの耐性グラム陽性球菌にも抗菌スペクトラムを有しており, 効果が期待されている. また, 本薬はほかの抗MRSA薬とは異なり, 血中濃度モニタリングを行う必要がなく, 腎機能に応じた用量調節が不要で, 生物学的利用率が高く経口薬でも静脈投与と同等の効果が得られる.
AbstractList 「緒言」Linezolid(LZD)は, オキサゾリジノン系の抗菌薬で, 我が国の添付文書に記載されている適応菌種は, methicillin-resistant Staphylococcus aureus(MRSA)およびvancomycin-resistant Enterococcus faecium(VRE)であるが, methicillin-resistant Staphylococcus epidermidis(MRSE)を含むmethicillin-resistant coagulase negative stapylococcus(MRCNS), penicillin-resistant Streptococcus pneumoniaeなどの耐性グラム陽性球菌にも抗菌スペクトラムを有しており, 効果が期待されている. また, 本薬はほかの抗MRSA薬とは異なり, 血中濃度モニタリングを行う必要がなく, 腎機能に応じた用量調節が不要で, 生物学的利用率が高く経口薬でも静脈投与と同等の効果が得られる.
Author 掛屋, 弘
山田, 康一
新宅, 治夫
永山, 勝也
時政, 定雄
中村, 安孝
櫻井, 紀宏
西川, 武司
Author_xml – sequence: 1
  fullname: 中村, 安孝
  organization: 大阪市立大学医学部附属病院薬剤部
– sequence: 2
  fullname: 櫻井, 紀宏
  organization: 大阪市立大学医学部附属病院薬剤部
– sequence: 3
  fullname: 山田, 康一
  organization: 大阪市立大学医学部附属病院感染制御部
– sequence: 4
  fullname: 時政, 定雄
  organization: 大阪市立大学大学院医学研究科発達小児医学
– sequence: 5
  fullname: 西川, 武司
  organization: 大阪市立大学医学部附属病院薬剤部
– sequence: 6
  fullname: 新宅, 治夫
  organization: 大阪市立大学大学院医学研究科発達小児医学
– sequence: 7
  fullname: 永山, 勝也
  organization: 大阪市立大学医学部附属病院薬剤部
– sequence: 8
  fullname: 掛屋, 弘
  organization: 大阪市立大学医学部附属病院感染制御部
BookMark eNo1kM1Kw0AUhQdR8HfpY6TOTCaZZFlEq1Bwo-BuGCczmpCmJdGFroxSpQr-bJRiV6JYEEV3Kvg0MYm-haPVzb0H7j3fudxxMBw1IwnANIIVyybuTBC0NkRSIajiuGQIjCHHwQYirjustUlswyR4dRRMJYm_BqHlQowsewyI_Ok0b59l6WPZfSsPnovdu_z2_ePloTzbL16u8qfz8vIwS--z9ChLz7O947ofyZ1m6HvaUvQ6-dGrtmRpP3_s5O3-r77_urjO0q5eLm56n_2TSTCieJjIqb8-AVbm55ZnF4z6Um1xtlo3AhOZ0MCUUyoodImQBEFKXNtTlkKKK4xspaTkHAphKgfbHnUotrDjKUcKjqXtQWFOgNqA25CeL3jYjEJ9LAuaW3Gkc5m3ZrU2eNxgGCKLQUgQwro5DOqX_RQXWxRTm2pSdUAKkk2-Llkr9hs83mY83vRFqJG_z2YEMU3Q9cf_PxM6ggXc_Ab5iJt4
ContentType Journal Article
Copyright 2015 日本医療薬学会
Copyright_xml – notice: 2015 日本医療薬学会
CorporateAuthor 大阪市立大学医学部附属病院感染制御部
大阪市立大学医学部附属病院薬剤部
大阪市立大学大学院医学研究科臨床感染制御学
大阪市立大学大学院医学研究科発達小児医学
CorporateAuthor_xml – name: 大阪市立大学大学院医学研究科臨床感染制御学
– name: 大阪市立大学大学院医学研究科発達小児医学
– name: 大阪市立大学医学部附属病院薬剤部
– name: 大阪市立大学医学部附属病院感染制御部
DOI 10.5649/jjphcs.41.894
DatabaseTitleList
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1882-1499
EndPage 899
ExternalDocumentID db5pharm_2015_004112_008_0894_08992572767
article_jjphcs_41_12_41_894_article_char_ja
GroupedDBID .LE
5GY
ALMA_UNASSIGNED_HOLDINGS
JSF
KQ8
MOJWN
RJT
ABJNI
ID FETCH-LOGICAL-j3130-27a77c7094ce4107496df5f1faf216ffeeaa0cc3f826d7872528df8eca2e6d0c3
ISSN 1346-342X
IngestDate Thu Jul 10 16:14:13 EDT 2025
Wed Apr 05 04:38:57 EDT 2023
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 12
Language Japanese
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-j3130-27a77c7094ce4107496df5f1faf216ffeeaa0cc3f826d7872528df8eca2e6d0c3
OpenAccessLink https://www.jstage.jst.go.jp/article/jjphcs/41/12/41_894/_article/-char/ja
PageCount 6
ParticipantIDs medicalonline_journals_db5pharm_2015_004112_008_0894_08992572767
jstage_primary_article_jjphcs_41_12_41_894_article_char_ja
PublicationCentury 2000
PublicationDate 20151210
PublicationDateYYYYMMDD 2015-12-10
PublicationDate_xml – month: 12
  year: 2015
  text: 20151210
  day: 10
PublicationDecade 2010
PublicationTitle 医療薬学
PublicationTitleAlternate 医療薬学
PublicationYear 2015
Publisher 一般社団法人日本医療薬学会
日本医療薬学会
Publisher_xml – name: 一般社団法人日本医療薬学会
– name: 日本医療薬学会
References 19) Jungbluth GL, Welshman IR, Hopkins NK, Linezolid pharmacokinetics in pediatric patients: An overview, Pediatr Infect Dis J, 2003, 22, S153-S157.
16) Saiman L, Goldfarb J, Kaplan SA, Wible K, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB, Safety and tolerability of linezolid in children, Pediatr Infect Dis J, 2003, 22, S193-S200.
11) Simon A, Müllenborn E, Prelog M, Schenk W, Holzapfel J, Ebinger F, et al: Use of linezolid in neonatal and pediatric inpatient facilities―results of a retrospective multicenter survey, Eur J Clin Microbiol Infect Dis, 2012, 31, 1435-1442.
15) Meissner HC, Townsend T, Wenman W, Kaplan SL, Morfin MR, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB, Hematologic effects of linezolid in young children, Pediatr, Infect Dis J, 2003, 22, S186-S192.
8）日本化学療法学会, 日本感染症学会, MRSA 感染症の治療ガイドライン作成委員会編, “MRSA 感染症の治療ガイドライン”改訂版, 日本化学療法学会, 東京, 2014
5）浜田幸宏, 関めぐみ, 田村和敬, 尾鳥勝也, 松原　肇, 花木秀明, 黒山政一, 矢後和夫, 砂川慶介, 小児MRSA感染症に対するLZDの使用経験, 化学療法の領域, 2011, 27, 139-148.
1) Brier ME, Stalker DJ, Aronoff GR, Batts DH, Ryan KK, O'Grady M, Hopkins NK, Jungbluth GL, Pharmacokinetics of linezolid in subjects with renal dysfunction, Antimicrob Agents Chemother, 2003, 47, 2775-2780.
10) Chiappini E, Conti C, Galli L, Martino M, Clinical efficacy and tolerability of linezolid in pediatric patients: A systemic review, Clin Ther, 2010, 32, 66-88.
4) Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak MJ, Talan DA, Chambers HF, Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children, Infectious Diseases Society of America, Clin Infect Dis, 2011, 52, 18-55.
18) Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, Kuter DJ, Hematologic effects of linezolid: Summary of clinical experience, Antimicrob Agents Chemother, 2002, 46, 2723-2726.
12) Kaplan SL, Deville JG, Yogev R, Morfin MR, Wu E, Adler S, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB, Linezolid Pediatric Study Group, Linezolid Pediatric Study Group, Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children, Pediatr Infect Dis J, 2003, 22, 677-686.
14) Smith PF, Birmingham MC, Noskin GA, Meagher AK, Forrest A, Rayner CR, Schentag JJ, Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Grampositive infections in cancer patients with neutropenia, Ann Oncol, 2003, 14, 795-801.
9）日本臨床腫瘍学会編, “発熱性好中球減少症（FN）診療ガイドライン”, 東京, 南江堂, 2012
3) Gee T, Ellis R, Marshall G, Andrews J, Ashby J, Wise R, Pharmacokinetics and tissue penetration of linezolid following multiple oral doses, Antimicrob Agents Chemother, 2001, 45, 1843-1846.
2) Moellering RC, Linezolid: the first oxazolidinone antimicrobial, Ann Intern Med, 2003, 138, 135-142.
17) Tavil B, Balci YI, Yildirim I, Tavil Y, Secmeer G, Ceyhan M, Tuncer M, Linezolid-induced reversible bicytopenia in a 4-year-old boy with methicillin-resistant Staphylococcus aureus bacteremia, Pediatr Hematol Oncol, 2008, 25, 67-71.
6) Shinjo M, Iketani O, Watanabe K, Shimomura N, Kudo M, Yamagishi H, Shimada H, Sugita K, Takahashi T, Mori T, Hasegawa N, Iwata S, Safety and efficacy of linezolid in 16 infants and children in Japan. J Infect Chemother, 2012, 18, 591-596.
7）深沢千絵, 朽名　悟, 星野　直, 小児におけるlinezolid 静注薬使用例37件の検討, 日本化学療法学会雑誌, 2013, 61, 504-509
13) Wang JL, Hsueh PR, Therapeutic options for infections due to vancomycin-resistant enterococci, Expert Opin Pharmacother, 2009, 10, 785-796.
References_xml – reference: 9）日本臨床腫瘍学会編, “発熱性好中球減少症（FN）診療ガイドライン”, 東京, 南江堂, 2012．
– reference: 16) Saiman L, Goldfarb J, Kaplan SA, Wible K, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB, Safety and tolerability of linezolid in children, Pediatr Infect Dis J, 2003, 22, S193-S200.
– reference: 3) Gee T, Ellis R, Marshall G, Andrews J, Ashby J, Wise R, Pharmacokinetics and tissue penetration of linezolid following multiple oral doses, Antimicrob Agents Chemother, 2001, 45, 1843-1846.
– reference: 8）日本化学療法学会, 日本感染症学会, MRSA 感染症の治療ガイドライン作成委員会編, “MRSA 感染症の治療ガイドライン”改訂版, 日本化学療法学会, 東京, 2014．
– reference: 6) Shinjo M, Iketani O, Watanabe K, Shimomura N, Kudo M, Yamagishi H, Shimada H, Sugita K, Takahashi T, Mori T, Hasegawa N, Iwata S, Safety and efficacy of linezolid in 16 infants and children in Japan. J Infect Chemother, 2012, 18, 591-596.
– reference: 11) Simon A, Müllenborn E, Prelog M, Schenk W, Holzapfel J, Ebinger F, et al: Use of linezolid in neonatal and pediatric inpatient facilities―results of a retrospective multicenter survey, Eur J Clin Microbiol Infect Dis, 2012, 31, 1435-1442.
– reference: 17) Tavil B, Balci YI, Yildirim I, Tavil Y, Secmeer G, Ceyhan M, Tuncer M, Linezolid-induced reversible bicytopenia in a 4-year-old boy with methicillin-resistant Staphylococcus aureus bacteremia, Pediatr Hematol Oncol, 2008, 25, 67-71.
– reference: 12) Kaplan SL, Deville JG, Yogev R, Morfin MR, Wu E, Adler S, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB, Linezolid Pediatric Study Group, Linezolid Pediatric Study Group, Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children, Pediatr Infect Dis J, 2003, 22, 677-686.
– reference: 7）深沢千絵, 朽名　悟, 星野　直, 小児におけるlinezolid 静注薬使用例37件の検討, 日本化学療法学会雑誌, 2013, 61, 504-509．
– reference: 13) Wang JL, Hsueh PR, Therapeutic options for infections due to vancomycin-resistant enterococci, Expert Opin Pharmacother, 2009, 10, 785-796.
– reference: 5）浜田幸宏, 関めぐみ, 田村和敬, 尾鳥勝也, 松原　肇, 花木秀明, 黒山政一, 矢後和夫, 砂川慶介, 小児MRSA感染症に対するLZDの使用経験, 化学療法の領域, 2011, 27, 139-148.
– reference: 2) Moellering RC, Linezolid: the first oxazolidinone antimicrobial, Ann Intern Med, 2003, 138, 135-142.
– reference: 4) Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak MJ, Talan DA, Chambers HF, Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children, Infectious Diseases Society of America, Clin Infect Dis, 2011, 52, 18-55.
– reference: 10) Chiappini E, Conti C, Galli L, Martino M, Clinical efficacy and tolerability of linezolid in pediatric patients: A systemic review, Clin Ther, 2010, 32, 66-88.
– reference: 18) Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, Kuter DJ, Hematologic effects of linezolid: Summary of clinical experience, Antimicrob Agents Chemother, 2002, 46, 2723-2726.
– reference: 19) Jungbluth GL, Welshman IR, Hopkins NK, Linezolid pharmacokinetics in pediatric patients: An overview, Pediatr Infect Dis J, 2003, 22, S153-S157.
– reference: 15) Meissner HC, Townsend T, Wenman W, Kaplan SL, Morfin MR, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB, Hematologic effects of linezolid in young children, Pediatr, Infect Dis J, 2003, 22, S186-S192.
– reference: 14) Smith PF, Birmingham MC, Noskin GA, Meagher AK, Forrest A, Rayner CR, Schentag JJ, Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Grampositive infections in cancer patients with neutropenia, Ann Oncol, 2003, 14, 795-801.
– reference: 1) Brier ME, Stalker DJ, Aronoff GR, Batts DH, Ryan KK, O'Grady M, Hopkins NK, Jungbluth GL, Pharmacokinetics of linezolid in subjects with renal dysfunction, Antimicrob Agents Chemother, 2003, 47, 2775-2780.
SSID ssib005902156
ssib003116159
ssib002484604
ssib000871962
ssib023157658
ssj0069027
ssib060196744
Score 2.0190604
Snippet 「緒言」Linezolid(LZD)は, オキサゾリジノン系の抗菌薬で, 我が国の添付文書に記載されている適応菌種は, methicillin-resistant Staphylococcus aureus(MRSA)およびvancomycin-resistant Enterococcus...
SourceID medicalonline
jstage
SourceType Publisher
StartPage 894
Title 小児の発熱性好中球減少症におけるLinezolidの有効性と安全性に関する検討
URI https://www.jstage.jst.go.jp/article/jjphcs/41/12/41_894/_article/-char/ja
http://mol.medicalonline.jp/library/journal/download?GoodsID=db5pharm/2015/004112/008&name=0894-0899j
Volume 41
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX 医療薬学, 2015/12/10, Vol.41(12), pp.894-899
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR1da9RAMNT6Ioj4ifWLe3D71KtJbrPZ9cnkLkdRlAot9C0kuQQ5tC22fWifPKVKK2j7ohT7JIqFYqlvVfA_-B_O3Om_cGY3uUuLYNWXZdnMzszO7GZnkt0ZTbtq60aoxzYrC5NbZRpYejkMKKYEDENhxIwnMt3b7TtsbJLenLKmBo58K5xaWpgPR6Ol394r-RetQhvoFW_J_oVme0ihAeqgXyhBw1AeSsfEs4irE17HCreI0IlXAduQOB7xbCIEcR2scEZcg3gMjzU4NgI70LFGPEpcTpyaBAY8FYSBFuFmmIUhHwEGO8fsZhXuZBWEgYpJuAuObbw0cx_k0GeDEVElXEgOHeKKAhsKhkt-vBzGki0HYICoIIIRx8yJih5RBHYoUvE49uVe0eCWOKvEdTOBQBcAQ1RVSbdGnN63yYI8gOuaHFmBNWgXtT4sQ7YQL0UpCwsJuBT5zjrV-7AWyt9VwqQoWGwBadgZSa4X8WZsMglbz9AJR8rAJSrXXf6lxrDw1Et2ZhfXluxno4KV6NU4_yQCyUcViBQ2qQpl5QqVaeh7u5gKH5avVrOwJ3GVRTo3b1Q-qoM7p8UoBp5tNmfvRXOj1Bjt9doXjLwRWrMYUt3H8fkYrM0wfZnIFOCxELAFmDazj2hHTXDcMKfIrbtFg9-GV34hYJ2BHkchgJxAG7RnIIPzAf5w_789w2hOMl-DsrUYgMv0SblEVBRdHMy1fUMB-7IJ3haG0Tj-QP0BVZFoCsbkxEntROYFlhy1pE9pA83gtDY8rsLIL46UJvq3IudGSsOl8X6A-cUzWpTuvkyX19qtne7Gl-7TT51HH9L3X7_vfeyuPensvUl317uvn7Vb2-3Waru13n78vLcuoUtncyVd_Qxd2q2tdGclXd6S9e2fr962WxsA3Hm3-WPrxVltsu5NVMfKWbKUcrMCdmjZtAPbjmxd0CimeMpasEZiJUYSJKbBkiSOg0CPokrCTdaAXdq0TN5IeBwFZswaelQ5pw1Oz0zH57WS0AMaCqqHcRxS1mBhSK0ojDg4V4YNFv2Qdl0J059VEXH87A3oK5n71PBhWkCJkyJ_hrdI_WYwpN3YpwA_e5_O-YeeWxf-H8VF7Vh_hV7SBucfLsSXwbuYD6_ICfsL2bf1RA
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E5%B0%8F%E5%85%90%E3%81%AE%E7%99%BA%E7%86%B1%E6%80%A7%E5%A5%BD%E4%B8%AD%E7%90%83%E6%B8%9B%E5%B0%91%E7%97%87%E3%81%AB%E3%81%8A%E3%81%91%E3%82%8BLinezolid%E3%81%AE%E6%9C%89%E5%8A%B9%E6%80%A7%E3%81%A8%E5%AE%89%E5%85%A8%E6%80%A7%E3%81%AB%E9%96%A2%E3%81%99%E3%82%8B%E6%A4%9C%E8%A8%8E&rft.jtitle=%E5%8C%BB%E7%99%82%E8%96%AC%E5%AD%A6&rft.au=%E4%B8%AD%E6%9D%91%E5%AE%89%E5%AD%9D&rft.au=%E6%AB%BB%E4%BA%95%E7%B4%80%E5%AE%8F&rft.au=%E5%B1%B1%E7%94%B0%E5%BA%B7%E4%B8%80&rft.au=%E6%99%82%E6%94%BF%E5%AE%9A%E9%9B%84&rft.date=2015-12-10&rft.pub=%E6%97%A5%E6%9C%AC%E5%8C%BB%E7%99%82%E8%96%AC%E5%AD%A6%E4%BC%9A&rft.issn=1346-342X&rft.volume=41&rft.issue=12&rft.spage=894&rft.epage=899&rft_id=info:doi/10.5649%2Fjjphcs.41.894&rft.externalDocID=db5pharm_2015_004112_008_0894_08992572767
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1346-342X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1346-342X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1346-342X&client=summon